| [1] |
WANG H, YU L, HUANG P, et al. Tumor-associated exosomes are involved in hepatocellular carcinoma tumorigenesis, diagnosis, and treatment[J]. J Clin Transl Hepatol, 2022, 10( 3): 496- 508. DOI: 10.14218/JCTH.2021.00425. |
| [2] |
|
| [3] |
VILLANUEVA A. Hepatocellular carcinoma[J]. N Engl J Med, 2019, 380( 15): 1450- 1462. DOI: 10.1056/nejmra1713263. |
| [4] |
HADE MD, SUIRE CN, SUO ZC. Mesenchymal stem cell-derived exosomes: Applications in regenerative medicine[J]. Cells, 2021, 10( 8): 1959. DOI: 10.3390/cells10081959. |
| [5] |
HADE MD, SUIRE CN, MOSSELL J, et al. Extracellular vesicles: Emerging frontiers in wound healing[J]. Med Res Rev, 2022, 42( 6): 2102- 2125. DOI: 10.1002/med.21918. |
| [6] |
MITANI F, LIN JY, SAKAMOTO T, et al. Asteltoxin inhibits extracellular vesicle production through AMPK/mTOR-mediated activation of lysosome function[J]. Sci Rep, 2022, 12( 1): 6674. DOI: 10.1038/s41598-022-10692-0. |
| [7] |
WILLMS E, CABAÑAS C, MÄGER I, et al. Extracellular vesicle heterogeneity: Subpopulations, isolation techniques, and diverse functions in cancer progression[J]. Front Immunol, 2018, 9: 738. DOI: 10.3389/fimmu.2018.00738. |
| [8] |
SINHA D, ROY S, SAHA P, et al. Trends in research on exosomes in cancer progression and anticancer therapy[J]. Cancers, 2021, 13( 2): 326. DOI: 10.3390/cancers13020326. |
| [9] |
PAPADAKOS SP, DEDES N, PERGARIS A, et al. Exosomes in the treatment of pancreatic cancer: A moonshot to PDAC treatment?[J]. Int J Mol Sci, 2022, 23( 7): 3620. DOI: 10.3390/ijms23073620. |
| [10] |
ZHAO L, PEI RF, DING YR, et al. LOXL4 shuttled by tumor cells-derived extracellular vesicles promotes immune escape in hepatocellular carcinoma by activating the STAT1/PD-L1 axis[J]. J Immunother, 2024, 47( 2): 64- 76. DOI: 10.1097/CJI.0000000000000496. |
| [11] |
MAO XW, ZHOU LY, TEY SK, et al. Tumour extracellular vesicle-derived Complement Factor H promotes tumorigenesis and metastasis by inhibiting complement-dependent cytotoxicity of tumour cells[J]. J Extracell Vesicles, 2020, 10( 1): e12031. DOI: 10.1002/jev2.12031. |
| [12] |
YANG Y, MAO FF, GUO L, et al. Tumor cells derived-extracellular vesicles transfer miR-3129 to promote hepatocellular carcinoma metastasis by targeting TXNIP[J]. Dig Liver Dis, 2021, 53( 4): 474- 485. DOI: 10.1016/j.dld.2021.01.003. |
| [13] |
SHIBATA C, OTSUKA M, SHIMIZU T, et al. Extracellular vesicle-mediated RNA editing may underlie the heterogeneity and spread of hepatocellular carcinoma in human tissue and in vitro[J]. Oncol Rep, 2023, 50( 5): 194. DOI: 10.3892/or.2023.8631. |
| [14] |
MAO XW, TEY SK, YEUNG CLS, et al. Nidogen 1-enriched extracellular vesicles facilitate extrahepatic metastasis of liver cancer by activating pulmonary fibroblasts to secrete tumor necrosis factor receptor 1[J]. Adv Sci, 2020, 7( 21): 2002157. DOI: 10.1002/advs.202002157. |
| [15] |
MEI PR, TEY SK, WONG SWK, et al. Actin-related protein 2/3 complex subunit 2-enriched extracellular vesicles drive liver cancer metastasis[J]. Hepatol Int, 2022, 16( 3): 603- 613. DOI: 10.1007/s12072-022-10338-3. |
| [16] |
LIU BHM, TEY SK, MAO XW, et al. TPI1-reduced extracellular vesicles mediated by Rab20 downregulation promotes aerobic glycolysis to drive hepatocarcinogenesis[J]. J Extracell Vesicles, 2021, 10( 10): e12135. DOI: 10.1002/jev2.12135. |
| [17] |
TAN WC, ZHANG JX, LIU LX, et al. Hsp90 inhibitor STA9090 induced VPS35 related extracellular vesicle release and metastasis in hepatocellular carcinoma[J]. Transl Oncol, 2022, 26: 101502. DOI: 10.1016/j.tranon.2022.101502. |
| [18] |
SICA A, MANTOVANI A. Macrophage plasticity and polarization: in vivo veritas[J]. J Clin Invest, 2012, 122( 3): 787- 795. DOI: 10.1172/JCI59643. |
| [19] |
PELLO OM, PIZZOL MD, MIROLO M, et al. Role of c-MYC in alternative activation of human macrophages and tumor-associated macrophage biology[J]. Blood, 2012, 119( 2): 411- 421. DOI: 10.1182/blood-2011-02-339911. |
| [20] |
ARORA S, DEV K, AGARWAL B, et al. Macrophages: Their role, activation and polarization in pulmonary diseases[J]. Immunobiology, 2018, 223( 4-5): 383- 396. DOI: 10.1016/j.imbio.2017.11.001. |
| [21] |
DENARDO DG, RUFFELL B. Macrophages as regulators of tumour immunity and immunotherapy[J]. Nat Rev Immunol, 2019, 19( 6): 369- 382. DOI: 10.1038/s41577-019-0127-6. |
| [22] |
BOUTILIER AJ, ELSAWA SF. Macrophage polarization states in the tumor microenvironment[J]. Int J Mol Sci, 2021, 22( 13): 6995. DOI: 10.3390/ijms22136995. |
| [23] |
DENARDO DG, BARRETO JB, ANDREU P, et al. CD4 + T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages[J]. Cancer Cell, 2009, 16( 2): 91- 102. DOI: 10.1016/j.ccr.2009.06.018. |
| [24] |
ZHOU JY, CHE JH, XU L, et al. Tumor-derived extracellular vesicles containing long noncoding RNA PART1 exert oncogenic effect in hepatocellular carcinoma by polarizing macrophages into M2[J]. Dig Liver Dis, 2022, 54( 4): 543- 553. DOI: 10.1016/j.dld.2021.07.005. |
| [25] |
LV SM, WANG JH, LI L. Extracellular vesicular lncRNA FAL1 promotes hepatocellular carcinoma cell proliferation and invasion by inducing macrophage M2 polarization[J]. J Physiol Biochem, 2023, 79( 3): 669- 682. DOI: 10.1007/s13105-022-00922-4. |
| [26] |
LI JJ, XUE JC, LING M, et al. MicroRNA-15b in extracellular vesicles from arsenite-treated macrophages promotes the progression of hepatocellular carcinomas by blocking the LATS1-mediated Hippo pathway[J]. Cancer Lett, 2021, 497: 137- 153. DOI: 10.1016/j.canlet.2020.10.023. |
| [27] |
NING JY, YE YN, BU DC, et al. Imbalance of TGF-β1/BMP-7 pathways induced by M2-polarized macrophages promotes hepatocellular carcinoma aggressiveness[J]. Mol Ther, 2021, 29( 6): 2067- 2087. DOI: 10.1016/j.ymthe.2021.02.016. |
| [28] |
PU J, XU ZM, NIAN JH, et al. M2 macrophage-derived extracellular vesicles facilitate CD8 + T cell exhaustion in hepatocellular carcinoma via the miR-21-5p/YOD1/YAP/β-catenin pathway[J]. Cell Death Discov, 2021, 7( 1): 182. DOI: 10.1038/s41420-021-00556-3. |
| [29] |
WANG XB, YE XX, CHEN YP, et al. Mechanism of M2 type macrophage-derived extracellular vesicles regulating PD-L1 expression via the MISP/IQGAP1 axis in hepatocellular carcinoma immunotherapy resistance[J]. Int Immunopharmacol, 2023, 124( Pt A): 110848. DOI: 10.1016/j.intimp.2023.110848. |
| [30] |
ZHANG HY, DENG T, GE SH, et al. Exosome circRNA secreted from adipocytes promotes the growth of hepatocellular carcinoma by targeting deubiquitination-related USP7[J]. Oncogene, 2019, 38( 15): 2844- 2859. DOI: 10.1038/s41388-018-0619-z. |
| [31] |
DENG L, WANG C, HE C, et al. Bone mesenchymal stem cells derived extracellular vesicles promote TRAIL-related apoptosis of hepatocellular carcinoma cells via the delivery of microRNA-20a-3p[J]. Cancer Biomark, 2021, 30( 2): 223- 235. DOI: 10.3233/CBM-201633. |
| [32] |
DENG J, KE H. Overcoming the resistance of hepatocellular carcinoma to PD-1/PD-L1 inhibitor and the resultant immunosuppression by CD38 siRNA-loaded extracellular vesicles[J]. Oncoimmunology, 2023, 12( 1): 2152635. DOI: 10.1080/2162402X.2022.2152635. |
| [33] |
BALDARI S, ROCCO GD, MAGENTA A, et al. Extracellular vesicles-encapsulated microRNA-125b produced in genetically modified mesenchymal stromal cells inhibits hepatocellular carcinoma cell proliferation[J]. Cells, 2019, 8( 12): 1560. DOI: 10.3390/cells8121560. |
| [34] |
CABIATI M, GIORGI ND, SALVADORI C, et al. Transcriptional level evaluation of osteopontin/miRNA-181a axis in hepatocellular carcinoma cell line-secreted extracellular vesicles[J]. Pathol Res Pract, 2022, 238: 154088. DOI: 10.1016/j.prp.2022.154088. |
DownLoad:
